Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma Journal Article
| Authors: | Leitao, M. M.; Soslow, R. A.; Baergen, R. N.; Olvera, N.; Arroyo, C.; Boyd, J. |
| Article Title: | Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma |
| Abstract: | Objective. The early natural history of epithelial ovarian carcinoma remains poorly understood. Mutation of the TP53 gene is common in advanced-stage (III-IV) ovarian cancers, but less well described in early stage (I-II) tumors. The purpose of this study was to perform a comprehensive analysis of TP53 mutation and p53 expression status in early stage ovarian carcinomas. Methods. Seventy-three cases of various histologic types, including 46 stage I and 27 stage II tumors, were subjected to direct sequence analysis of the entire TP53 coding region and exon-intron junctions as well as immunohistochemical assessment of p53 expression. Results. Overall, mutations were identified in 24 of 73 (34%) cases. However, a significant difference in the distribution of mutations among histologic types was observed; TP53 mutations were present in 14 of 21 (67%) serous cancers and 11 of 52 (21%) non-serous cancers (P = 0.0002). Mutations were equally common between stage I and stage II tumors of serous histology. With respect to the correlation between TP53 mutation and p53 immunopositivity, the sensitivity (58%), specificity (71%), positive predictive value (64%), and negative predictive value (83%) were not sufficiently robust to justify use of p53 expression as a surrogate or screen for mutation. Conclusions. These data indicate that TP53 mutation is common in early stage ovarian carcinomas of serous histology, with a mutation frequency comparable to that reported for advanced-stage tumors, and is therefore likely to occur early in the progression of the most common histologic variant of ovarian carcinoma. © 2004 Elsevier Inc. All rights reserved. |
| Keywords: | immunohistochemistry; human tissue; protein expression; gene mutation; human cell; sequence analysis; exon; frameshift mutation; mutation, missense; cancer staging; neoplasm staging; diagnostic accuracy; genetic analysis; ovarian cancer; ovarian neoplasms; gene expression; intron; protein p53; prediction; histology; tumor suppressor gene; correlation analysis; statistical significance; gene identification; ovary carcinoma; epithelial cells; tumor suppressor protein p53; genetic screening; p53; genes, p53; tp53; early stage; humans; human; female; priority journal; article |
| Journal Title: | Gynecologic Oncology |
| Volume: | 93 |
| Issue: | 2 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2004-05-01 |
| Start Page: | 301 |
| End Page: | 306 |
| Language: | English |
| DOI: | 10.1016/j.ygyno.2004.01.043 |
| PROVIDER: | scopus |
| PUBMED: | 15099937 |
| DOI/URL: | |
| Notes: | Gynecol. Oncol. -- Cited By (since 1996):47 -- Export Date: 16 June 2014 -- CODEN: GYNOA -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work